20160793 - Barredo Julio
-
Investigator:
Julio Barredo
Email
Coordinator: Eva Pavicic
+1 (305) 2437846
IRB: 20160793
SDG: Pediatric Cancer
Disease Site(s): Soft Tissue
Sponsor: Moffitt Cancer Center
Enrolling Sites:
JMH
SylvesterTitle: Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Eligibility Criteria - NCT02945800 *This information has been extracted from " www.clinicaltrials.gov"
TAPUR - Calfa, Carmen
-
Investigator:
Carmen Calfa
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20170529
SDG: Breast Cancer
Disease Site(s): Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
Sponsor: ASCO
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"
20200056 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator: Nailet Real Bestard
+1 (305) 2438173
IRB: 20200056
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
Sponsor: DECIPHERA
Enrolling Sites:
Sylvester
Title: A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"
20201131 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator: Nailet Real Bestard
+1 (305) 2438173
IRB: 20201131
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Stomach
Sponsor: DECIPHERA
Enrolling Sites:
Sylvester
Title: A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
Eligibility Criteria - NCT04530981 *This information has been extracted from " www.clinicaltrials.gov"
20201132 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator:
IRB: 20201132
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Soft Tissue
Sponsor: Tracon
Enrolling Sites:
Sylvester
Title: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy
Eligibility Criteria - NCT04480502 *This information has been extracted from " www.clinicaltrials.gov"
20201400 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator:
IRB: 20201400
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Soft Tissue
Sponsor: ETCTN
Enrolling Sites:
Sylvester
Title: A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Eligibility Criteria - NCT02923778 *This information has been extracted from " www.clinicaltrials.gov"
MATCH - Huang, Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20150671
SDG: Gynecologic Cancer
Disease Site(s): Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue
Sponsor: ECOG
Enrolling Sites:
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
SylvesterTitle: Molecular Analysis for Therapy Choice (MATCH)
Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"
20211131 - Jonczak Emily
-
Investigator:
Emily Jonczak
Email
Coordinator: Sonali Kumar
+1 (305) 2430279
IRB: 20211131
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bones and Joints
Sponsor: ETCTN
Enrolling Sites:
Plantation
SylvesterTitle: Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Eligibility Criteria - NCT04595747 *This information has been extracted from " www.clinicaltrials.gov"
CPI-006-001 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator: Rakhi Modak
+1 (305) 2437387
IRB: 20180279
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue
Sponsor: CP
Enrolling Sites:
Sylvester
Title: CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"
RTX-240-01 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator: Isabel Fernandez
+1 (305) 2435486
IRB: 20200686
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Multiple
Sponsor: Rubius Therapeutics
Enrolling Sites:
Sylvester
Title: PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB
Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"
20191009 - Pimentel Agustin
-
Investigator:
Agustin Pimentel
Email
Coordinator:
IRB: 20191009
SDG: Pancreatic, Liver, and Related Cancers
Disease Site(s): Bones and Joints,Lip, Oral Cavity and Pharynx
Sponsor: HOOKIPA PHARMA
Enrolling Sites:
Sylvester
Title: A Phase I/II Study of TheraT® Vector(s) Expressing HumanPapillomavirus 16 Positive (HPV 16+) Specific Antigens inPatients with HPV 16+ Confirmed Cancers
Eligibility Criteria - NCT04180215 *This information has been extracted from " www.clinicaltrials.gov"
AMC- 096 - Ramos, Juan Carlos
-
Investigator:
Juan Carlos Ramos
Email
Coordinator:
IRB: 20180804
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Kaposis sarcoma
Sponsor: AMC
Enrolling Sites:
Sylvester
Title: AMC-096: A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
Eligibility Criteria - NCT02799485 *This information has been extracted from " www.clinicaltrials.gov"
RPL-001-16 - Rodriguez, Estelamari
-
Investigator:
Estelamari Rodriguez
Email
Coordinator: Yanel Diaz Caro
3052438227
IRB: 20180802
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bladder,Breast-Female,Colon,Melanoma, skin
Sponsor: REPLIMUNE
Enrolling Sites:
Sylvester
Title: RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"
Anlotinib AL3818-US-004A - Trent, Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator:
IRB: 20170072
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Soft Tissue
Sponsor: ADVENCHEN LABORATORIES
Enrolling Sites:
Sylvester
Title: AL3818-US-004A: Phase III Study of AL3818 (Anlotinib) HydrochlorideMonotherapy in Subjects with Metastatic or AdvancedAlveolar Soft Part Sarcoma, Leiomyosarcoma and SynovialSarcoma
Eligibility Criteria - NCT03016819 *This information has been extracted from " www.clinicaltrials.gov"
180114: TMZ-GIST - Trent, Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator: Mirna Gonzalez
+1 (305) 2432441
IRB: 20200974
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Colon,Esophagus,Small Intestine,Soft Tissue,Stomach
Sponsor: University of California, San Diego
Enrolling Sites:
Sylvester
Title: An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Eligibility Criteria - NCT03556384 *This information has been extracted from " www.clinicaltrials.gov"
20201368 - Trent Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator:
IRB: 20201368
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Soft Tissue
Sponsor: SCCC
Enrolling Sites:
Plantation
SylvesterTitle: ctDNA-Guided Sunitinib And Regorafenib Therapy for Gastrointestinal Stromal Tumor (GIST)
20210831 - Trent Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator:
IRB: 20210831
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bones and Joints
Sponsor: ASTELLAS PHARMA US
Enrolling Sites:
Sylvester
Title: A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1
Eligibility Criteria - NCT04939701 *This information has been extracted from " www.clinicaltrials.gov"
20210970 - Trent Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator:
IRB: 20210970
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bones and Joints
Sponsor: Foghorn Therapeutics
Enrolling Sites:
Sylvester
Title: A phase 1, multicenter, open-label, dose escalation and expansion study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of intravenously administered fhd-609 in subjects with advanced synovial sarcoma
Eligibility Criteria - NCT04965753 *This information has been extracted from " www.clinicaltrials.gov"
20211225 - Trent Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator: Ravipal Luthra
IRB: 20211225
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bones and Joints
Sponsor: Cogent Biosciences
Enrolling Sites:
Sylvester
Title: (PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS